Genmab
- Market cap
- 22.54B
- P/E (TTM)i
- 28.97
- P/Bi
- 3.78
- EPSi
- 1.54
- Div yieldi
- 0.00%
- 52W posi
- 79%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.1 percentage points.
Institutional ownership
- Held by institutions
- 58.15% -1.07pp
- Institutions
- 591 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
2 filings tracked · 0 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Judith Klimovsky | Chief Development Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2025-06-16 | Judith Klimovsky | Chief Development Officer | Intent to Sell (Form 144) | -1,300 | $51.69 |
| 2024-02-29 | Judith Klimovsky | Chief Development Officer | Intent to Sell (Form 144) | -1,200 | $27.77 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:35:49 · For reference only, not investment advice and not tailored to your situation.